Comparison of 68Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4–20 ng/ml before the initial biopsy
Yu Li, Donghui Han, Peng Wu, Jing Ren, Shuaijun Ma, Jingliang Zhang, Wei Song, Xiaoyu Lin, Dian Jiao, Shengjia Shi, Fa Yang, Jieheng Wu, Ping Meng, Weihong Wen, Fei Kang, Jing Wang, Weijun Qin
Abstract
Abstract The study was aimed at assessing the diagnostic performance of 68 Ga-PSMA-617 PET/CT in the detection of prostate cancer (PCa) in patients with a prostate-specific antigen (PSA) level of 4–20 ng/ml and to compare its efficacy with that of multiparametric MRI (mpMRI). We analyzed the data of 67 consecutive patients with PSA levels of 4–20 ng/ml who almost simultaneously underwent 68 Ga-PSMA-617 PET/CT and mpMRI. 68 Ga-PSMA-617 PET/CT and mpMRI diagnostic performances were compared via receiver operating characteristic (ROC) curve analysis. Of the 67 suspected PCa cases, 33 had pathologically confirmed PCa. 68 Ga-PSMA-617 PET/CT showed a patient-based sensitivity, specificity, and positive and negative predictive values (PPVs and NPVs) of 87.88%, 88.24%, 87.88%, and 88.24%, respectively. The corresponding values for mpMRI were 84.85%, 52.94%, 63.64%, and 78.26%. The area under the curve values for 68 Ga-PSMA-617 PET/CT and mpMRI were 0.881 and 0.689, respectively. 68 Ga-PSMA-617 PET/CT showed a better diagnostic performance than mpMRI in the detection of PCa in patients with PSA levels of 4–20 ng/ml.